Literature DB >> 25943124

Endophenotypes in Schizophrenia for the Perinatal Period: Criteria for Validation.

Randal G Ross1, Robert Freedman2.   

Abstract

Endophenotypes are disease-associated phenotypes that are thought to reflect the neurobiological or other mechanisms that underlie the more overt symptoms of a psychiatric illness. Endophenotypes have been critical in understanding the genetics, neurobiology, and treatment of schizophrenia. Because psychiatric illnesses have multiple causes, including both genetic and nongenetic risk factors, an endophenotype linked to one of the mechanisms may be expressed more frequently than the disease itself. However, in schizophrenia research, endophenotypes have almost exclusively been studied in older adolescents or adults who have entered or passed through the age of risk for the disorder. Yet, schizophrenia is a neurodevelopmental disorder where prenatal development starts a cascade of brain changes across the lifespan. Endophenotypes have only minimally been utilized to explore the perinatal development of vulnerability. One major impediment to the development of perinatally-useful endophenotypes has been the established validity criteria. For example, the criterion that the endophenotype be more frequently present in those with disease than those without is difficult to demonstrate when there can be a decades-long period between endophenotype measurement and the age of greatest risk for onset of the disorder. This article proposes changes to the endophenotype validity criteria appropriate to perinatal research and reviews how application of these modified criteria helped identify a perinatally-usable phenotype of risk for schizophrenia, P50 sensory gating, which was then used to propose a novel perinatal primary prevention intervention.
© The Author 2015. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  biological markers; endophenotype; infant; schizophrenia; sensory gating

Mesh:

Substances:

Year:  2015        PMID: 25943124      PMCID: PMC4466194          DOI: 10.1093/schbul/sbv054

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  141 in total

1.  Disease prediction in the at-risk mental state for psychosis using neuroanatomical biomarkers: results from the FePsy study.

Authors:  Nikolaos Koutsouleris; Stefan Borgwardt; Eva M Meisenzahl; Ronald Bottlender; Hans-Jürgen Möller; Anita Riecher-Rössler
Journal:  Schizophr Bull       Date:  2011-11-10       Impact factor: 9.306

2.  Theory of Mind in patients at clinical high risk for psychosis.

Authors:  Arielle D Stanford; Julie Messinger; Dolores Malaspina; Cheryl M Corcoran
Journal:  Schizophr Res       Date:  2011-07-14       Impact factor: 4.939

3.  Identification of young people at risk of psychosis: validation of Personal Assessment and Crisis Evaluation Clinic intake criteria.

Authors:  L J Phillips; A R Yung; P D McGorry
Journal:  Aust N Z J Psychiatry       Date:  2000-11       Impact factor: 5.744

4.  Nicotinic and muscarinic cholinergic receptor binding in the human hippocampal formation during development and aging.

Authors:  J A Court; S Lloyd; M Johnson; M Griffiths; N J Birdsall; M A Piggott; A E Oakley; P G Ince; E K Perry; R H Perry
Journal:  Brain Res Dev Brain Res       Date:  1997-07-18

5.  P50 sensory gating in panic disorder.

Authors:  Eduardo S Ghisolfi; Elizeth Heldt; Ana Paula Zanardo; Ivo M Strimitzer; Alexandre S Prokopiuk; Jefferson Becker; Aristides V Cordioli; Gisele G Manfro; Diogo R Lara
Journal:  J Psychiatr Res       Date:  2006-04-17       Impact factor: 4.791

6.  Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome.

Authors:  Patrick D McGorry; Barnaby Nelson; Lisa J Phillips; Hok Pan Yuen; Shona M Francey; Annette Thampi; Gregor E Berger; G Paul Amminger; Magenta B Simmons; Daniel Kelly; Grad Dip; Andrew D Thompson; Alison R Yung
Journal:  J Clin Psychiatry       Date:  2012-11-27       Impact factor: 4.384

7.  Impaired P50 sensory gating in post-traumatic stress disorder secondary to urban violence.

Authors:  Eduardo S Ghisolfi; Regina Margis; Jefferson Becker; Ana Paula Zanardo; Ivo M Strimitzer; Diogo R Lara
Journal:  Int J Psychophysiol       Date:  2004-02       Impact factor: 2.997

8.  Sensory gating in young children with autism: relation to age, IQ, and EEG gamma oscillations.

Authors:  Elena V Orekhova; Tatiana A Stroganova; Andrey O Prokofyev; Gudrun Nygren; Cristopher Gillberg; Mikael Elam
Journal:  Neurosci Lett       Date:  2008-02-06       Impact factor: 3.046

9.  Physiology of schizophrenia, bipolar disorder, and schizoaffective disorder.

Authors:  Laura F Martin; Mei-Hua Hall; Randal G Ross; Gary Zerbe; Robert Freedman; Ann Olincy
Journal:  Am J Psychiatry       Date:  2007-12       Impact factor: 18.112

Review 10.  Is clinical intervention in the ultra high risk phase effective?

Authors:  Philip McGuire; Sudhakar Selvaraj; Oliver Howes
Journal:  Braz J Psychiatry       Date:  2011-10       Impact factor: 2.697

View more
  5 in total

1.  Editorial Board Changes for 2018.

Authors:  William T Carpenter; Paul D Shepard; Laura M Rowland; Janet L Smith
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

2.  New Targets for Prevention of Schizophrenia: Is It Time for Interventions in the Premorbid Phase?

Authors:  Larry J Seidman; Merete Nordentoft
Journal:  Schizophr Bull       Date:  2015-04-29       Impact factor: 9.306

3.  Male fetus susceptibility to maternal inflammation: C-reactive protein and brain development.

Authors:  Sharon K Hunter; M Camille Hoffman; Angelo D'Alessandro; Kathleen Noonan; Anna Wyrwa; Robert Freedman; Amanda J Law
Journal:  Psychol Med       Date:  2019-12-02       Impact factor: 7.723

4.  The mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophrenia.

Authors:  Guy Griebel; Philippe Pichat; Denis Boulay; Vanessa Naimoli; Lisa Potestio; Robert Featherstone; Sukhveen Sahni; Henry Defex; Christophe Desvignes; Franck Slowinski; Xavier Vigé; Olivier E Bergis; Rosy Sher; Raymond Kosley; Sathapana Kongsamut; Mark D Black; Geoffrey B Varty
Journal:  Sci Rep       Date:  2016-10-13       Impact factor: 4.379

5.  Working memory deficits in schizophrenia are associated with the rs34884856 variant and expression levels of the NR4A2 gene in a sample Mexican population: a case control study.

Authors:  Elizabeth Ruiz-Sánchez; Janet Jiménez-Genchi; Yessica M Alcántara-Flores; Carlos J Castañeda-González; Carlos L Aviña-Cervantes; Petra Yescas; María Del Socorro González-Valadez; Nancy Martínez-Rodríguez; Antonio Ríos-Ortiz; Martha González-González; María E López-Navarro; Patricia Rojas
Journal:  BMC Psychiatry       Date:  2021-02-09       Impact factor: 3.630

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.